|
Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome |
HAYES, Inc |
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem:
Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6% to 20% of women of reproductive age. It is characterized by oligoovulation (menstrual irregularity), hyperandrogenism (increased testosterone levels), and polycystic ovaries. Obesity is a common feature of PCOS, affecting approximately 40% to 80% of women diagnosed with the syndrome. Weight loss is a central component of treatment for women with PCOS who are overweight or obese. Weight reduction can decrease androgen effects, increase ovulation, and improve insulin sensitivity.
Technology Description:
Glucagon-like Peptide-1(GLP-1) receptor agonists are a class of drugs that mimic the effects of the naturally occurring gut hormone GLP-1. The GLP-1 hormone, which is released in the gastrointestinal tract after a meal, stimulates insulin secretion, inhibits glucagon release, delays gastric emptying, reduces food intake, and normalizes fasting and postprandial insulin secretion. GLP-1 receptor agonists have similar, but more enduring, effects to the naturally occurring hormone.
Controversy: Prescribing information for Saxenda (liraglutide) and Byetta (exenatide) states that these drugs must be used in conjunction with a reduced-calorie diet and exercise. However, the randomized controlled trials evaluated in this report did not implement diet and exercise programs in conjunction with GLP-1 receptor agonists. Further, use of GLP-1 receptor agonists could potentially cause serious adverse events (AEs). While the most frequently occurring AEs associated with GLP-1 receptor agonists include mild to moderate gastrointestinal discomfort (e.g., nausea, diarrhea, and vomiting), the FDA has issued a black box warning for
Saxenda (liraglutide) concerning the potential risk of thyroid C-cell tumors. The FDA also warns that Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2.
Key Questions:
Are GLP-1 receptor agonists effective in treating obesity in adult women with PCOS? How do GLP-1
receptor agonists compare with placebo or other active drug therapies? Are GLP-1 receptor
agonists safe? Have definitive patient selection criteria been identified for GLP-1 receptor agonists? Indexing Status Subject indexing assigned by CRD MeSH Female; Glucagon-Like Peptide-1 Receptor; Humans; Obesity; Polycystic Ovary Syndrome Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32018000068 Date abstract record published 14/02/2018 |
|
|
|